Population Health Research Institute
Arrhythmia

EXPLORE Xa (Completed)
A Phase 2, Randomized, Parallel group, Dose finding, Multicentre, Multinational study of the safety, Tolerability and pilot efficacy of three blinded doses of the Oral Factor Xa Inhibitor Betrixaban compared with Open Label Dose adjusted Warfarin in patients with non-valvular Atrial Fibrillation (EXPLORE Xa)

< back

The trial evaluates stroke prevention in patients with atrial fibrillation (AF). Hypothesis: In patients with non-valvular AF, orally administered betrixaban will provide similar or better efficacy and safety than warfarin and it will offer the advantage of not requiring dose adjustments due to INRs outside the target range of 2.0 to 3.0 and a more consistent level of anticoagulation over time.

Study Design: Treatment, Randomized, Double Blind, Active Control, Parallel Assignment, Safety Study.

Intervention: Factor Xa Inhibitor Betrixaban.

Length of Study: 2 years

# of Patients: 500

Patient Populations: Atrial fibrillation.


Presentations

Available upon study completion.


Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Not available at this time.

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca